Sangamo plunges after Pfizer ends pact for hemophilia drug

Quick Summary:

Sangamo Therapeutics Inc.shares fell the most in 16 years after Pfizer Inc.ended the two companies’ partnership to develop a new gene therapy to treat hemophilia A.

Shares of Pfizer gained as much as 0.9 percent at the market open.

The company’s market value was just below $500 million before the Pfizer news hit.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Bloomberg News

Category: BusinessStartups

Markets: Philippines

Topics: Shares Million Fell Drug Pfizer Therapy Hemophilia Sangamo Gene Company Been

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-01-01 @ 11:26:08 (3 days ago)

News Timezone: GMT +8:00

News Source URL: businessmirror.com.ph

Language: English

Article Length: 358 words

Reading Time: 2 minutes read

Sentences: 17 lines

Sentence Length: 22 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Business Mirror

News ID: 24802407

View Article Analysis

About Business Mirror

Main Topics: BusinessStartups

Official Website: businessmirror.com.ph

Update Frequency: 30 posts per day

Year Established: 2005

Headquarters: Philippines

News Last Updated: 22 hours ago

Coverage Areas: Philippines

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Local / Regional

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #37

Publisher Details

Frequently Asked Questions